Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.

JS, Montaner; MT, Schechter; A, Rachlis; J, Gill; R, Beaulieu; C, Tsoukas; J, Raboud; B, Cameron; H, Salomon; L, Dunkle; L, Smaldone; MA, Wainberg

doi:10.7326/0003-4819-123-8-199510150-00001

Public

Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.

Shared by NobleBlocks on Oct 1, 1995 • 12:00 AM UTC

Authors:

Montaner JS

Schechter MT

Rachlis A

Abstract

<h4>Objective</h4>To compare the safety and efficacy of didanosine with that of continued zidovudine therapy in persons with human immunodeficiency virus (HIV) infection who had received zidovudine for at least 6 months and had CD4 cell counts of 200 to 500 CD4 cells/mm3.<h4>Design</h4>Double-blind,...

Discussions